Blog

Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD

blog.png
September 21, 2017 Blood Cancer PDX Models: Focus on Acute Myeloid Leukemia‎ A number of our previous posts have covered the benefits of patient-derived xenografts (PDX), usually focusing on models derived from solid tumors. But these highly predictive preclinical models can also be developed from blood cancer. LEARN MORE
September 19, 2017 Beginners Guide: Humanized Drug Target Immuno-Oncology Models Our recent post compared stable vs transiently humanized models, which are needed when human-specific therapeutics are ... LEARN MORE
September 14, 2017 First Type 2 Diabetes Publication Comparing Pros and Cons of Two Preclinical Continuous Glucose Monitoring Systems Significant Correlation between Blood Glucose Levels Measured by Glucometer and both the Dexcom G4 Platinum and HD-XG ... LEARN MORE
September 12, 2017 CD137: An Important Target in T Cell Co-Stimulation Following on from OX40, our TNF superfamily posts continue with CD137, another important target in T cell ... LEARN MORE
September 7, 2017 When to Use Stable vs Transiently Humanized I/O Models As immunotherapeutics continue to dominate oncology headlines and research, more preclinical studies are requiring ... LEARN MORE
September 5, 2017 Treatment Approaches for EGFR-Mutated Lung Cancer Each year, around 140,000 people worldwide (15,000 in the United States alone) are diagnosed with epidermal growth ... LEARN MORE
August 31, 2017 Recent Type 2 Diabetes Publication Demonstrates Preclinical Study Benefits of Continuous Glucose Monitoring Daily Blood Glucose Fluctuations in Normal and Diabetic NHPs from Wang et al. J Endocrinol Invest 2017;40(9): 967-977. Hypoglycemia has long been recognized as a major barrier to achieving normoglycemia with intensive therapy, and has therefore been investigated in terms of its impact on counter regulatory mechanisms as well as cognitive function1,2. ... LEARN MORE
August 29, 2017 OX40 Agonists: Boosting Cancer Immunotherapy Following our recent post covering the Tumor Necrosis Factor Superfamily of Ligands and Receptors, we’re going to take ... LEARN MORE
August 24, 2017 Mouse Allograft Models: A GEMM-Derived Efficacy Testing Platform Genetically engineered mouse models (GEMM) were reviewed in a recent post, as immunocompetent, murine immunity models ... LEARN MORE
August 22, 2017 The Beginners Guide to Neoantigens and Immuno-Oncology Studies \Neoantigens are mutation associated antigens that arise from nonsynonomous somatic variations acquired in tumors ... LEARN MORE
August 17, 2017 How to Optimize your Non GLP Toxicology Studies Most new drug candidates fail in the clinic because they are not efficacious or are not safe. Optimizing non-clinical safety studies can save time, money, and animal resources in the long run. LEARN MORE
August 15, 2017 Genetically Engineered Mouse Models (GEMM) for I/O Studies Led largely by the growth in immuno-oncology research, older immunocompetent model use continues to rise. These models ... LEARN MORE
August 10, 2017 Tumor Necrosis Factor Superfamily of Ligands and Receptors 101 Members of the large Tumor Necrosis Factor (TNF) superfamily (TNFSF) of proteins participate in the coordinated ... LEARN MORE
August 8, 2017 Syngeneic Tumor Mouse Models: The Pros and Cons Immunotherapeutics are bringing remarkable survival rates for certain cancer patients, but they are also bringing some ... LEARN MORE
August 3, 2017 How Patient Derived Tumor Grafts (PDX) Accelerate Early Drug Development × Over the year’s cancer research and drug development have moved from developing “simple” chemotherapies which stop ... LEARN MORE